[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495649":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":48,"centralContacts":52,"locations":53,"responsibleParty":73,"collaborators":75,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":52,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":52,"enrollmentInfo":88,"targetDuration":52,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":52,"overallStatus":55,"whyStopped":52,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"City of Hope Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment (ST-SBRT)","EXPERIMENTAL","Patients undergo ST-SBRT on study. Patients also undergo collection of blood samples at screening and on study and undergo CT at screening, on study, and during follow up.",[13,14,15],"Procedure: Biospecimen Collection","Procedure: Computed Tomography","Radiation: Stereotactic Body Radiation Therapy",[17,26,39],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"PROCEDURE","Biospecimen Collection","Undergo collection of blood samples",[9],[23,24,25],"Biological Sample Collection","Biospecimen Collected","Specimen Collection",{"type":18,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Computed Tomography","Undergo CT",[9],[31,32,33,34,35,36,37,38],"CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized Tomography","CT","CT Scan","tomography",{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"RADIATION","Stereotactic Body Radiation Therapy","Undergo ST-SBRT",[9],[45,46,47],"SABR","SBRT","Stereotactic Ablative Body Radiation Therapy",[49],{"name":50,"affiliation":5,"role":51},"Yi-Jen Chen","PRINCIPAL_INVESTIGATOR",null,[54],{"facility":5,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"RECRUITING","Duarte","California","91010","United States","US",{"type":62,"coordinates":63},"Point",[64,65],-117.97729,34.13945,{"lat":65,"lon":64},[68,72],{"name":50,"role":69,"phone":70,"phoneExt":52,"email":71},"CONTACT","626-218-4589","yichen@coh.org",{"name":50,"role":51,"phone":52,"phoneExt":52,"email":52},{"type":74,"investigatorFullName":52,"investigatorTitle":52,"investigatorAffiliation":52,"oldNameTitle":52,"oldOrganization":52},"SPONSOR",[76],{"name":77,"class":78},"National Cancer Institute (NCI)","NIH","100495649","spatiotemporal-stereotactic-body-radiation-therapy-for-the-treatment-of-patients-with-polymetastatic-solid-tumors-100495649",false,"NCT05733949","Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors","A Pilot Study of Spatiotemporal SBRT for Poly-Metastatic Cancer","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Age: \\>= 18 years\n* Karnofsky performance status \\> 60\n* Poly-metastatic disease, \\> 5 lesions, and with at least one lesion \\> 2.0 cm, with limited treatment options, and ineligible for or in progression under the standard systemic therapy\n* Pre-screening assessment confirms that the intervention can be administered without exceeding dose constraint guidelines\n* Patients with brain metastases can be included but brain metastases must be treated prior to enrollment and follow up magnetic resonance imaging (MRI) 3 months after treatment shows stable findings\n* Spinal cord metastases are allowed as long as treatment with or without radiation is completed\n* Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints\n* Life expectancy \\>= 3 months in the opinion of the treating investigators\n* Off systemic therapy for at least one month prior and one month after study intervention\n\nExclusion Criteria:\n\n* Judgement by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements\n* Those not eligible for SBRT after review by a radiation oncologist\n* Serous medical comorbidities precluding radiotherapy\n* Unable to undergo a CT scan\n* Pregnant and\u002For breastfeeding women are excluded from this study as these agents may have the potential for teratogenic or abortifacient effects. Female patients of childbearing potentially must have a negative urine or serum pregnancy test within 72 hours prior to receiving therapy\n* On active systemic therapy\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)","ALL","18 Years",{"count":89,"type":90},20,"ESTIMATED","INTERVENTIONAL",[93],"EARLY_PHASE1","This clinical trial evaluates the safety and effectiveness of spatiotemporal stereotactic body radiation therapy (ST-SBRT) in treating patients with solid tumors that have spread to other parts of the body (polymetastatic). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. ST-SBRT is designed to deliver radiation directly to the core of the tumor, while keeping the radiation exposure of the area around the tumor at minimal dosage.",[96],"Metastatic Malignant Solid Neoplasm","2026-08-18",{"date":99,"type":100},"2026-08-19","ACTUAL",{"date":102,"type":100},"2023-04-27",{"date":104,"type":90},"2027-10-11",{"name":5,"class":6},1]